Summary
I graduated from Athens Medical School in 1983 and completed internal medicine training in 1990. In 1995 I was awarded my PhD from the University of London on monoclonal antibodies in Head and Neck Cancer. I completed my cancer specialty training as a lecturer at St George's hospital studying the immunology of melanoma cell vaccine therapeutics. I was appointed as a Senior Lecturer at the University of Hull in 1999 part of the founding team of Hull York Medical School, where I became professor of Cancer Medicine in 2012.
I am also a honorary consultant in the Hull University Teaching Hospitals NHS Trust (HUTH) having also been the Director of R&D till 2021. I treat and am involved in clinical trials in pancreaticobiliary, kidney cancer and melanoma and have particular clinical and basic science research interest in cancer associated thrombosis (CAT).
I have been national and international chief investigator for a number of studies in CAT and have worked on international guideline bodies for this condition. I have published widely in CAT with particular focus on the thromboprophylaxis of the ambulatory cancer patient and the management of incidental pulmonary embolism in cancer patients.
Journal Article
Calcitonin gene-related peptide and intermedin induce phosphorylation of p44/42 MAPK in primary human lymphatic endothelial cells in vitro
Hasan, S. R., Manolis, D., Stephenson, E., Ryskiewicz-Sokalska, O. A., Maraveyas, A., & Nikitenko, L. L. (2024). Calcitonin gene-related peptide and intermedin induce phosphorylation of p44/42 MAPK in primary human lymphatic endothelial cells in vitro. Cellular Signalling, 121, Article 111261. https://doi.org/10.1016/j.cellsig.2024.111261
Quantitative proteomics reveals CLR interactome in primary human cells
Manolis, D., Hasan, S., Maraveyas, A., O'Brien, D. P., Kessler, B. M., Kramer, H., & Nikitenko, L. L. (2024). Quantitative proteomics reveals CLR interactome in primary human cells. Journal of Biological Chemistry, 300(6), Article 107399. https://doi.org/10.1016/j.jbc.2024.107399
Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)
Vasudev, N. S., Ainsworth, G., Brown, S., Pickering, L., Waddell, T., Fife, K., Griffiths, R., Sharma, A., Katona, E., Howard, H., Velikova, G., Maraveyas, A., Brown, J., Pezaro, C., Tuthill, M., Boleti, E., Bahl, A., Szabados, B., Banks, R. E., Brown, J., …Powles, T. (2024). Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM). Journal of Clinical Oncology, 42(3), 312-323. https://doi.org/10.1200/JCO.23.00236
Feasibility of delivering supervised exercise training following surgical resection and during adjuvant chemotherapy for pancreatic ductal adenocarcinoma (PRECISE): a case series
Brown, M., O’Connor, D., Turkington, R., Eatock, M., Vince, R., Hulme, C., Bowdery, R., Robinson, R., Wadsley, J., Maraveyas, A., & Prue, G. (2023). Feasibility of delivering supervised exercise training following surgical resection and during adjuvant chemotherapy for pancreatic ductal adenocarcinoma (PRECISE): a case series. BMC Sports Science, Medicine and Rehabilitation, 15(1), Article 116. https://doi.org/10.1186/s13102-023-00722-3